Research Analysts Issue Forecasts for Integer Q3 Earnings

Integer Holdings Corporation (NYSE:ITGR) – Equities researchers at Zacks Research cut their Q3 2026 earnings estimates for Integer in a report issued on Thursday, May 21st. Zacks Research analyst Team now forecasts that the medical equipment provider will earn $1.68 per share for the quarter, down from their previous estimate of $1.73. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Integer’s current full-year earnings is $6.04 per share. Zacks Research also issued estimates for Integer’s FY2026 earnings at $6.05 EPS, Q1 2027 earnings at $1.50 EPS, Q2 2027 earnings at $1.60 EPS, Q4 2027 earnings at $1.90 EPS, Q1 2028 earnings at $1.65 EPS and FY2028 earnings at $7.20 EPS.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.21 by ($0.01). The company had revenue of $439.58 million for the quarter, compared to analyst estimates of $426.48 million. Integer had a return on equity of 12.83% and a net margin of 7.64%.The firm’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter last year, the company posted $1.31 earnings per share. Integer has set its FY 2026 guidance at 5.830-6.400 EPS.

A number of other research firms also recently weighed in on ITGR. Weiss Ratings upgraded Integer from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, February 24th. Truist Financial increased their price objective on Integer from $95.00 to $97.00 and gave the company a “buy” rating in a report on Friday, February 20th. Wells Fargo & Company increased their price objective on Integer from $72.00 to $84.00 and gave the company an “equal weight” rating in a report on Friday, February 20th. Wall Street Zen downgraded Integer from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Finally, Citigroup decreased their price objective on Integer from $92.00 to $89.00 and set a “neutral” rating for the company in a report on Friday, May 1st. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $98.29.

Integer Stock Performance

NYSE ITGR opened at $89.34 on Monday. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of 22.28, a PEG ratio of 2.10 and a beta of 0.67. Integer has a twelve month low of $62.00 and a twelve month high of $123.78. The stock has a fifty day simple moving average of $86.78 and a 200 day simple moving average of $81.86. The company has a quick ratio of 2.38, a current ratio of 3.75 and a debt-to-equity ratio of 0.77.

Insider Buying and Selling

In other Integer news, VP Tommy P. Thomas sold 825 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $85.00, for a total transaction of $70,125.00. Following the sale, the vice president owned 4,381 shares of the company’s stock, valued at approximately $372,385. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.10% of the company’s stock.

Institutional Trading of Integer

A number of institutional investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its position in shares of Integer by 48.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 117 shares in the last quarter. Salomon & Ludwin LLC boosted its position in shares of Integer by 46.8% during the 4th quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 118 shares in the last quarter. Kestra Advisory Services LLC boosted its position in shares of Integer by 0.6% during the 4th quarter. Kestra Advisory Services LLC now owns 21,424 shares of the medical equipment provider’s stock worth $1,680,000 after purchasing an additional 136 shares in the last quarter. Orion Porfolio Solutions LLC boosted its position in shares of Integer by 1.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 9,755 shares of the medical equipment provider’s stock worth $1,200,000 after purchasing an additional 138 shares in the last quarter. Finally, Lido Advisors LLC boosted its position in shares of Integer by 5.5% during the 4th quarter. Lido Advisors LLC now owns 2,887 shares of the medical equipment provider’s stock worth $226,000 after purchasing an additional 151 shares in the last quarter. Institutional investors own 99.29% of the company’s stock.

Key Headlines Impacting Integer

Here are the key news stories impacting Integer this week:

• Negative Sentiment: Zacks Research lowered its FY2026 earnings estimate for Integer to $6.05 per share from $6.40, signaling softer profit expectations for the medical equipment maker.
• Negative Sentiment: The firm also trimmed near-term estimates for Q3 2026, Q1 2027, Q2 2027, and FY2028, reinforcing concerns that earnings growth may be more uneven than previously expected.
• Negative Sentiment: A Globe and Mail item titled “Integer Holdings Earnings Call Flags Tough 2026” suggests the company’s latest commentary pointed to a difficult operating year ahead, which may be pressuring sentiment. Article Title

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.